Results 181 to 190 of about 349,413 (344)

Transcriptomic and proteomic profiling shows dysregulated immune and metabolic pathways in arrhythmogenic cardiomyopathy

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Arrhythmogenic cardiomyopathy (ACM) is a hereditary heart disease characterized by fibrofatty myocardial replacement and a predisposition to malignant ventricular arrhythmias. The underlying pathomechanisms remain incompletely understood, and specific disease markers are sparse.
Deniz Akdis   +11 more
wiley   +1 more source

Blockade of platelet alpha2B-adrenergic receptors in patients with coronary artery disease: a novel antiaggregant mechanism [PDF]

open access: bronze, 2013
Maria Marketou   +9 more
openalex   +1 more source

Beta‐blockers in patients with heart failure with reduced ejection fraction and concomitant chronic obstructive pulmonary disease: Cardiovascular and respiratory outcomes

open access: yesEuropean Journal of Heart Failure, EarlyView.
In total, 5084 patients from Swedish registries with both heart failure (HF) with reduced ejection fraction (HFrEF) and chronic obstructive pulmonary disease (COPD) were included. Confounding was handled by overlap weighting based on propensity scores for beta‐blocker use. Patients were followed up for 5 years, or until death, emigration from Sweden or
Benedikt N. Beer   +17 more
wiley   +1 more source

Quantitative [<sup>18</sup>F]FDOPA PET/CT for the characterization of biochemical phenotypes in paraganglioma and pheochromocytoma. [PDF]

open access: yesEJNMMI Rep
Dahlmann P   +19 more
europepmc   +1 more source

European Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action

open access: yesEuropean Journal of Heart Failure, EarlyView.
Heart failure (HF) and atrial fibrillation (AF) are major global health challenges with rising prevalence and significant morbidity, mortality, and healthcare burden. Despite advances in HF management, AF remains a critical comorbidity that worsens outcomes and requires ad hoc treatment strategies, increasing the risk of non‐adherence and side effects.
Mark Luedde   +24 more
wiley   +1 more source

Cholinergic suppression of heart rate acceleration during intrinsic optogenetic activation of sympathetic cardiac neurons in perfused hearts. [PDF]

open access: yesAm J Physiol Heart Circ Physiol
Russo R   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy